// App-Quantinova.ai

250 : Radium-223 in metastatic castration resistant prostate cancer: Progression free survival and pain scores—Real-world single-institution experience.

Researchers

Presenter

  • Amarnath Challapalli

Principal Investigators

  • Serena Hilman

  • Sue Cowley

  • Susan Masson

  • Dorothy Grifiths

  • Rajendra Persad

  • Kathryn Mitchell

  • Rebecca Huckett

  • Rosemary Greenwood

  • Eleanor Compton

  • Amit Bahl

Medical Centers

  • Bristol Haematology and Oncology Centre, Bristol, United Kingdom

  • Bristol Haematology and Oncology Centre, Bristol, United Kingdom

  • University of Bristol, Bristol, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Amyloid P compound, Serum

  • Prostate specific antigen

Drug/Treatment

  • Alkaline phosphatase

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved